Intercept Pharmaceuticals Falls As CEO Says It May Need Help Big Pharma's Help
Published: Jan 14, 2014
Intercept Pharmaceuticals Inc. (ICPT) fell the most in more than a year as Chief Executive Officer Mark Pruzanski said he may need the help of a larger drugmaker to bring the company’s experimental liver-disease treatment to market. The complex and poorly recognized liver disorder, called nonalcoholic steatohepatitis or NASH, occurs most often in people who are overweight or have diabetes. Marked by a slow but dangerous buildup of fat and inflammation that can damage the liver, it’s symptomless early on and complicated to diagnose.
Help employers find you! Check out all the jobs and post your resume.